Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Heterocyclic carbon compounds containing a hetero ring...
Patent
1994-04-25
1997-10-28
Richter, Johann
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Heterocyclic carbon compounds containing a hetero ring...
514364, 514599, 514520, 514532, 514570, 514640, 514648, 514617, 514726, 544176, 548131, 558401, 560101, 562491, 564 74, 564265, 564305, 564181, 568809, A61K 3142, A61K 31535, C07D26530, C07D27106
Patent
active
056818351
ABSTRACT:
Prescribed herein are novel non-steroidal ligands for the estrogen receptor which possess tissue-dependent estrogenic and antiestrogenic activity as well as methods for making the same and their applications in treating a variety of disease states.
REFERENCES:
patent: 3341537 (1967-09-01), Richardson et al.
patent: 3493606 (1970-02-01), Richardson
patent: 3637856 (1972-01-01), Landquist et al.
patent: 4198435 (1980-04-01), Richardson
patent: 4206234 (1980-06-01), Richardson
patent: 4307111 (1981-12-01), Crawley
patent: 4536516 (1985-08-01), Harper et al.
patent: 4623660 (1986-11-01), Richardson
patent: 4803227 (1989-02-01), Brandes et al.
patent: 4851433 (1989-07-01), Kraus
patent: 4859695 (1989-08-01), McKissick et al.
patent: 4894373 (1990-01-01), Young
patent: 4960937 (1990-10-01), Woschina et al.
patent: 5047431 (1991-09-01), Schickaneder et al.
patent: 5393785 (1995-02-01), Labrie et al.
Jordan et al., Endocrine Pharmacology of Antiestrogens as Antitumor Agents, Endocrine Reviews, vol. 11, No. 4, pp. 578-610 (1990).
Lerner et al., Development of antiestrogens and their use in breast cancer: eighth Cain Memorial Award Lecture, Cancer Res. 50:4177, Jul. 15, 1990.
Jordan et al., Structural requirements for the pharmacological activity of non-steroidal antiestrogens in vitro, Mol. Pharm, 26:272 (1984).
Jordan et al., A monohydroxylated metabolite of tamoxifen with potent antioestrogenic activity, J. Endocrinol. 75:305 (1977).
Jordan et al., Importance of the alkylaminoethyoxy side chain for the estrogenic and antiestrogenic actions of tamoxifen and trioxifene in the immature rat uterus., Mol Cell Endocrinol. 27:291 (1982).
Jarman et al., Analogues of tamoxifen: the role of the basic side chain. Application of a whole cell oestrogen-receptor binding assay to N-oxides and quaternery salts. AntiCancer Drug Design 1:259 (1986).
Murphy et al., Structural components necessary for the antiestrogenic activity of tamoxifen, J. Steroid Biochem 34:407 (1989).
Harper et al., Contrasting endocrine activities of cis and trans isomers in a series of substituted triphenylethylenes, Nature, 212:87 (1966).
Jordan et al., Geometric isomers of substituted triphenylenes and antiestrogen action. Endocrinology 108:1353, 1981.
Katzenellenbogen et al., Bioactivities, estrogen receptor interactions and plasminogen activator-inducing activities of tamoxifen and hydroxytamoxifen isomers in MCF-7 human breast cancer cells. Center Res. 44:112 (1984).
Katzenellenbogen et al., Facile geometric isomerization of phenolic nonsteroidal estrogens and antiestrogens: limitations to the interpretation of experiments characterizing the activity of individual isomers, J. Steroid Biochem 22:589 (1985).
McCague et al., Synthesis and estrogen receptor binding of 5H-benzocyclo-heptene, a non-isomerizable analogue of tamoxifen. X-Ray Crystallographic Studies, J. Med. Chem. 29:2053 (1986).
McCague et al., Non-isomerizable analogues of (Z)- and (E)-4 hydroxytamoxifen. Synthesis and endocrinological properties of substituted diphenylbenzocycloheptenes, J. Med. Chem 31:1285 (1988).
McCague et al., Non-isomerizable antiestrogens related to tamoxifen, J. Steroid Biochem, 31:545 (1988).
Katzenellenbogen et al., Efficient and highly selective covalent labeling 258:3487 (1983).
Harlow et al., Identification of crystein-530 as the covalent attachment site of an affinity labeling estrogen (ketonoestrolaziridine) and antiestrogen (tamoxifenaziridine) on the human estrogen receptor. J. Biol. Chem, 264:17476 (1989).
Lees et al. Identification of two transactivation domains in the mouse oestrogen receptor. Nucleic Acids Res 17:5477 (1989).
Fawell et al., Inhibition of estrogen receptor-DNA binding by the "pure" antiestrogen ICI 164,384 appears to be mediated by impaired receptor dimerization, Proc. Natl. Acad Sci, USA 87:6883 (1990).
Love et al., Bone mineral density in women with breast cancer treated for at least two years with tamoxifen, Breast Cancer Res. Treat. 12:297 (1988).
Turken et al., Effects of tamoxifen on spinal bone density in women with breast cancer, J. Natl. Cancer Inst. 81:1086 (1989).
Fentiman et al., Bone mineral content of women receiving tamoxifen for mastalgia, Br. J. Cancer, 60:262 (1989).
Fornander et al., Long-term adjuvant tamoxifen in early breast cancer: effect on bone mineral density in postmenopausal women, J. Clin. Oncol 8:1019 (1990).
Rossner et al., Serum lipoproteins after breast cancer surgery and effects of tamoxifen. Atherosclerosis 53:339 (1984).
Bruning et al., Tamoxifen, serum lipoproteins and cardiovascular risk, Br. J. Cancer 58:497 (1988).
Bertelli et al., Adjuvant tamoxifen in primary breast cancer: influence on plasma lipids and antithrombin III levels. Breast Cancer Res. Treat 12:307 (1988).
Caleffi et al., Effect of tamoxifen on oestrogen binding, lipid and lipoprotein concentrations and blood clotting parameters in premenopausal women with breast pain, J. Endocrinol, 199:335 (1988).
Bagdade et al., Effect of tamoxifen treatment on plasma lipids and tipoproteins lipid composition, J. Clin Endocrinol Metab, 70:1132 (1990).
Love et al., Lipid and lipoprotein effects of tamoxifen therapy in postmenopausal patients with node negative breast cancer, JNCI 82:1327 (1990).
McCague et al., Derivatives of Tamoxifen, Dependence of Anteistrogenicity on the 4-Substituent, J. Med. Chem vol. 32, pp. 2527-2533 (1989).
Duax et al., Structural Features which distinguish estrogen agonists and antagonists, J. Steroid Biochem vol. 27, pp. 271-280 (1987).
Robertson et al., "Antiestrogen Basicity- Activity Relationships: A Comparison of the Estrogen Receptor Binding and Antiuterotropic Potencies of Several Analogues of (Tamoxifen, Nolvadex) Having Altered Basicity", J. Med. Chem. 25, pp. 167-171 (1982). Month Not Available.
Dadswell Charles E.
Glaxo Wellcome Inc.
Richter Johann
Stockton Laura L.
LandOfFree
Non-steroidal ligands for the estrogen receptor does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Non-steroidal ligands for the estrogen receptor, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Non-steroidal ligands for the estrogen receptor will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-1026235